November 2021

Contents

Editorial

• HTB: no. 11 – plus HIV and COVID-19 (Nov/Dec 2021)

• IAS review on HIV cure research: A global scientific strategy to cure HIV (2021)

Conference reports

• 18th International European AIDS Conference (EACS 2021)

• Lenacapavir: drug resistance after viral rebound in treatment experienced participants

• Implications of historical M184V on use of dual dolutegravir/lamivudine ART

• Stopping long-acting cabotegravir/rilpivirine: 1 in 5 trial participants didn’t restart oral ART within eight weeks

• Islatravir plus doravirine dual ART: 144 week follow-up from phase 2 study

• HIV-specific mental health services across the EU

Antiretrovirals

• NICE approves long-acting cabotegravir and rilpivirine injections in England and Wales

• MSD/Merck stop once-weekly NNRTI MK-8507: islatravir studies continue with closer monitoring

Other news

• UK oral history project for young people who were born with HIV

COVID-19: investigational drugs

• Colchicine: no clinical benefits against COVID-19 in pooled analysis of RCTs

• Eli Lilly withdraw EU application for bNAbs etesevimab and bamlanivimab

PDFs

• HTB: no. 11 – plus HIV and COVID-19 (30 November 2021)